Pentapeptide-18 (Leuphasyl): Evidence, Mechanism & Status

Pentapeptide-18 — trade name Leuphasyl, from Lipotec (now Lubrizol Life Science) — is a synthetic five-amino-acid peptide marketed as a topical, needle-free alternative to expression-line treatments. It is most often discussed alongside the SNAP-25-mimetic peptides because it is deliberately combined with them, yet it works by an entirely different route. This monograph separates the mechanism that makes it interesting from the evidence that does — and does not — support it.46

This article is informational and editorial content for educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Pentapeptide-18 is a cosmetic ingredient, not an approved drug. Concentrations are reported strictly as seen in the published literature and cosmetic-use data for completeness — not as recommendations. Consult a licensed clinician before using any peptide-containing product, especially if pregnant or breastfeeding.

What is Pentapeptide-18 and how does it work?

Pentapeptide-18 is the INCI name for the cosmetic active sold as Leuphasyl. Its sequence is Tyr-D-Ala-Gly-Phe-Leu, molecular formula C₂₉H₃₉N₅O₇, molecular weight about 569.7 Da, with PubChem CID 10099522 and CAS 64963-01-5.8 Structurally it is a leucine-enkephalin analog: native leu-enkephalin is Tyr-Gly-Gly-Phe-Leu, and Leuphasyl swaps the position-2 glycine for D-alanine, a non-natural D-amino acid that resists peptidase cleavage — extending the functional half-life while preserving opioid-receptor affinity. You can confirm its identity directly on the public chemistry record at PubChem CID 10099522.78

The mechanism is presynaptic and receptor-mediated. Pentapeptide-18 binds enkephalin/opioid receptors (the delta-opioid type is emphasized) on the motor nerve terminal; receptor coupling releases inhibitory Gi/Go protein subunits, which close voltage-gated Ca²⁺ channels and open K⁺ channels, hyperpolarizing the terminal. With less calcium entering, the calcium-dependent fusion of acetylcholine vesicles is reduced, so less acetylcholine reaches the muscle and the repeated micro-contractions that etch dynamic expression lines are dampened.47 The effect is explicitly described as a dimmer switch, not an off switch, and milder than botulinum toxin while preserving facial expressivity.6

How does it relate to the SNAP-25 peptides?

The reason Pentapeptide-18 keeps company with the SNAP-25 peptides is that it solves a different part of the same problem. Acetyl hexapeptide-8 (Argireline) and acetyl octapeptide-3 (SNAP-8) act postsynaptically and downstream, mimicking the N-terminus of the SNAP-25 protein to destabilize SNARE-complex assembly and impair vesicle docking and fusion directly. Pentapeptide-18 acts presynaptically and upstream, lowering the calcium signal that triggers fusion in the first place.61

This matters for reading product labels. A serum pairing Pentapeptide-18 with a SNAP-25-mimetic peptide is targeting both the calcium trigger and the SNARE fusion machinery, whereas a single-agent formula leans on just one. The combination logic is mechanistically sound even where the quantitative synergy claims are not independently confirmed.5

What is the evidence by indication?

There is exactly one evidenced indication — reduction in the appearance of dynamic expression lines — and the evidence behind it is uneven. The table separates the human signal from the manufacturer and preclinical material.

The principal independent dataset is Dragomirescu and colleagues, The Efficiency and Safety of Leuphasyl — A Botox-Like Peptide, Cosmetics 2014. Twenty volunteers applied emulsions at 0.5%, 1% and 2% over the corrugator supercilii and orbicularis oculi for two months, with wrinkles measured by an imaging device. Only the 2% concentration produced a significant improvement, establishing a practical threshold and reducing wrinkle scoring by roughly 35% in the frontal/inter-brow region and 28% periorbitally.12 The limitations are why this is graded B rather than A: small n, no placebo-controlled randomized arm, single center, short duration, and instrument-scored endpoints.1

The most-quoted numbers — and the entire synergy narrative — come from Lipotec/Lubrizol proprietary data summarized in the Gorouhi and Maibach 2009 review. As reported over 28 days of twice-daily use, 5% Leuphasyl alone gave roughly 11-12% wrinkle reduction, 5% Argireline about 16%, and the 5%+5% combination about 25% — interpreted as synergistic.3 These are manufacturer-generated, not independently RCT-verified, and the inflated secondary figures circulating online ("up to 47%") compound the uncertainty — graded D.6 A separate 2026 study provides spectroscopic and molecular-interaction characterization but reports no clinical outcomes.9

What about delivery, dosing and safety?

A central caveat is delivery. At about 570 Da, Pentapeptide-18 sits just above the empirical "rule of 500" ceiling for efficient passive transdermal flux, and it is hydrophilic against a lipophilic stratum corneum — so meaningful penetration to the neuromuscular junction is questionable. By analogy to acetyl hexapeptide-8, where independent work found only a tiny fraction reaches the stratum corneum and none crosses to the dermis, modeled junctional concentrations of Leuphasyl have been estimated in the sub-nanomolar range, potentially below the threshold for delta-opioid activation. Benefit is therefore formulation- and delivery-dependent, and no validated human pharmacokinetic dataset exists.6

Reported strictly as information: the route is topical, leave-on only. The only concentration with human support is 2% w/w twice daily; commercial products commonly cite 2-5%, and the manufacturer's 28-day data used 5%. Application is advised across the full muscle field, not just on visible lines, with at least four weeks of consistent use before assessing effect.16 Topical tolerability is high — published cosmetic use reports no irritation, no allergic reactions and no serious adverse events, with effects fully reversible within days to weeks of stopping. Systemic absorption is considered negligible, so systemic opioid effects are not expected. The real gaps are unevaluated pregnancy and lactation safety, no long-term studies, and the infection risk of injecting unregulated gray-market vials.64

What is the regulatory and anti-doping status?

Pentapeptide-18 is regulated as a cosmetic ingredient, not a drug. Under the U.S. FD&C Act and the Modernization of Cosmetics Regulation Act there is no premarket approval requirement, no NDA or IND on file, and no FDA-approved therapeutic indication; a product making muscle- or structure-altering claims could be reclassified as a drug.11 In the EU it is a permitted cosmetic ingredient under Regulation (EC) No 1223/2009 and is not on the prohibited-substances annex, supplied commercially as trade materials such as Leuphasyl and SpecPed PP18P.710 For athletes, Pentapeptide-18 is not listed on the WADA Prohibited List, and ordinary topical cosmetic use is not a doping concern; only an off-label injectable "research chemical" form would even theoretically implicate the non-approved-substances catch-all.6

Bottom line. Pentapeptide-18 is a clever, safe, low-risk surface cosmetic whose genuine distinction is its presynaptic enkephalin mechanism — a real complement to the SNAP-25-mimetic peptides rather than a duplicate of them. What is reasonably supported (graded B) is a modest, concentration-dependent reduction in the appearance of expression lines at 2% or more over weeks to months, from one small open-label study. What is hyped (graded D) are the precise synergy percentages that dominate marketing copy, which trace to manufacturer data, and the "needle-free Botox" framing that overstates an effect explicitly milder than injection and constrained by poor transdermal delivery of a ~570 Da peptide. It is worth far less than its alternative-to-Botox marketing implies, and it is not a therapeutic agent.